Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$210.76 - $249.51 $1.31 Million - $1.55 Million
6,218 Added 431.21%
7,660 $1.76 Million
Q4 2023

Feb 02, 2024

BUY
$214.88 - $256.94 $309,856 - $370,507
1,442 New
1,442 $317,000
Q1 2023

Apr 27, 2023

BUY
$212.99 - $276.17 $1.36 Million - $1.76 Million
6,374 New
6,374 $1.43 Million
Q2 2021

Aug 12, 2021

SELL
$170.47 - $211.93 $1.48 Million - $1.84 Million
-8,668 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$153.94 - $174.85 $1 Million - $1.14 Million
6,517 Added 302.98%
8,668 $0
Q4 2020

Feb 02, 2021

BUY
$101.87 - $151.79 $219,122 - $326,500
2,151 New
2,151 $326,000
Q3 2020

Oct 14, 2020

SELL
$99.9 - $121.13 $306,093 - $371,142
-3,064 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$92.74 - $125.82 $284,155 - $385,512
3,064 New
3,064 $370,000
Q1 2020

Apr 29, 2020

SELL
$79.39 - $115.35 $135,518 - $196,902
-1,707 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$78.31 - $95.34 $133,675 - $162,745
1,707 New
1,707 $150,000
Q2 2019

Jul 26, 2019

SELL
$76.06 - $120.81 $231,070 - $367,020
-3,038 Closed
0 $0
Q1 2019

Apr 18, 2019

BUY
$107.15 - $126.84 $325,521 - $385,339
3,038 New
3,038 $0
Q4 2018

Jan 16, 2019

SELL
$101.4 - $128.73 $611,137 - $775,855
-6,027 Closed
0 $0
Q3 2018

Oct 23, 2018

SELL
$113.81 - $129.46 $3,186 - $3,624
-28 Reduced 0.46%
6,027 $770,000
Q2 2018

Jul 30, 2018

BUY
$101.14 - $118.31 $612,402 - $716,367
6,055 New
6,055 $685,000
Q1 2018

Apr 26, 2018

SELL
$107.21 - $151.94 $1.33 Million - $1.88 Million
-12,372 Closed
0 $0
Q4 2017

Jan 10, 2018

BUY
$118.58 - $151.28 $640,924 - $817,668
5,405 Added 77.58%
12,372 $1.83 Million
Q3 2017

Oct 25, 2017

BUY
$114.6 - $136.81 $798,418 - $953,155
6,967
6,967 $816,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.9B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.